159 related articles for article (PubMed ID: 34626839)
1. Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC.
Song Z; Lian S; Mak S; Chow MZ; Xu C; Wang W; Keung HY; Lu C; Kebede FT; Gao Y; Cheuk W; Cho WCS; Yang M; Zheng Z
J Thorac Oncol; 2022 Feb; 17(2):264-276. PubMed ID: 34626839
[TBL] [Abstract][Full Text] [Related]
2. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
[TBL] [Abstract][Full Text] [Related]
3. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
4. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
6. Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
Zheng J; Zhu Y; Sun K; Shen Q; Wang Y; Cao H; Lizaso A; Yu B; Lin J; Chen S; Zhou J; Zhou J
Lung Cancer; 2020 Aug; 146():209-216. PubMed ID: 32563740
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
de Figueiredo-Pontes LL; Wong DW; Tin VP; Chung LP; Yasuda H; Yamaguchi N; Nakayama S; Jänne PA; Wong MP; Kobayashi SS; Costa DB
J Thorac Oncol; 2014 Feb; 9(2):248-53. PubMed ID: 24419423
[TBL] [Abstract][Full Text] [Related]
8. Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC.
Zhang Y; Zeng L; Zhou C; Li Y; Wu L; Xia C; Jiang W; Hu Y; Liao D; Xiao L; Liu L; Yang H; Xiong Y; Guan R; Lizaso A; Mansfield AS; Yang N
J Thorac Oncol; 2020 Jun; 15(6):1027-1036. PubMed ID: 32112982
[TBL] [Abstract][Full Text] [Related]
9. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences.
Tabbò F; Muscarella LA; Gobbini E; Trombetta D; Castellana S; Rigutto A; Galetta D; Maiello E; Martelli O; Tiseo M; Scotti V; Ghilardi L; Gregorc V; Sergi C; Pilotto S; Del Conte A; Cappuzzo F; Cortinovis D; Osman G; Bareggi C; Di Maio M; Rossi A; Rossi G; Bria E; Volante M; Scagliotti GV; Graziano P; Novello S; Righi L
Eur J Cancer; 2022 Oct; 174():200-211. PubMed ID: 36044814
[TBL] [Abstract][Full Text] [Related]
10. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
Zhang SS; Nagasaka M; Zhu VW; Ou SI
Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
[TBL] [Abstract][Full Text] [Related]
11. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
Nilsson RJ; Karachaliou N; Berenguer J; Gimenez-Capitan A; Schellen P; Teixido C; Tannous J; Kuiper JL; Drees E; Grabowska M; van Keulen M; Heideman DA; Thunnissen E; Dingemans AM; Viteri S; Tannous BA; Drozdowskyj A; Rosell R; Smit EF; Wurdinger T
Oncotarget; 2016 Jan; 7(1):1066-75. PubMed ID: 26544515
[TBL] [Abstract][Full Text] [Related]
12. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
[TBL] [Abstract][Full Text] [Related]
13. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
14. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
[TBL] [Abstract][Full Text] [Related]
15. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
[TBL] [Abstract][Full Text] [Related]
16. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
[TBL] [Abstract][Full Text] [Related]
17. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
[TBL] [Abstract][Full Text] [Related]
18. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
19. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
[TBL] [Abstract][Full Text] [Related]
20. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
